These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Orexin 2 receptor-selective agonist danavorexton (TAK-925) promotes wakefulness in non-human primates and healthy individuals. Evans R; Kimura H; Nakashima M; Ishikawa T; Yukitake H; Suzuki M; Hazel J; Faessel H; Wu J; Hang Y; Alexander R; Rosen L; Hartman DS; Ratti E J Sleep Res; 2023 Oct; 32(5):e13878. PubMed ID: 36934366 [TBL] [Abstract][Full Text] [Related]
7. OX2R-selective orexin agonism is sufficient to ameliorate cataplexy and sleep/wake fragmentation without inducing drug-seeking behavior in mouse model of narcolepsy. Yamamoto H; Nagumo Y; Ishikawa Y; Irukayama-Tomobe Y; Namekawa Y; Nemoto T; Tanaka H; Takahashi G; Tokuda A; Saitoh T; Nagase H; Funato H; Yanagisawa M PLoS One; 2022; 17(7):e0271901. PubMed ID: 35867683 [TBL] [Abstract][Full Text] [Related]
8. [Development of a Therapeutic Drug for Narcolepsy]. Irukayama-Tomobe Y; Yanagisawa M Brain Nerve; 2018 Nov; 70(11):1255-1263. PubMed ID: 30416119 [TBL] [Abstract][Full Text] [Related]
9. The present and future of synthetic orexin receptor agonists. Saitoh T; Sakurai T Peptides; 2023 Sep; 167():171051. PubMed ID: 37422012 [TBL] [Abstract][Full Text] [Related]
10. The orexin receptor 2 (OX2R)-selective agonist TAK-994 increases wakefulness without affecting cerebrospinal fluid orexin levels in cynomolgus monkeys. Yamada R; Narita N; Ishikawa T; Kakehi M; Kimura H Pharmacol Biochem Behav; 2024 Jan; 234():173690. PubMed ID: 38061670 [TBL] [Abstract][Full Text] [Related]
11. Continuous intrathecal orexin delivery inhibits cataplexy in a murine model of narcolepsy. Kaushik MK; Aritake K; Imanishi A; Kanbayashi T; Ichikawa T; Shimizu T; Urade Y; Yanagisawa M Proc Natl Acad Sci U S A; 2018 Jun; 115(23):6046-6051. PubMed ID: 29784823 [TBL] [Abstract][Full Text] [Related]
12. Safety and pharmacodynamics of a single infusion of danavorexton in adults with idiopathic hypersomnia. Mignot E; Bogan RK; Emsellem H; Foldvary-Schaefer N; Naylor M; Neuwirth R; Faessel H; Swick T; Olsson T Sleep; 2023 Sep; 46(9):. PubMed ID: 36883238 [TBL] [Abstract][Full Text] [Related]
13. Novel biomarkers derived from the Maintenance of Wakefulness Test as predictors of sleepiness and response to treatment. Tracey B; Culp M; Fabregas S; Mignot E; Buhl DL; Volfson D Sleep; 2024 Jul; ():. PubMed ID: 38954525 [TBL] [Abstract][Full Text] [Related]
14. Sex-related differences within sleep-wake dynamics, cataplexy, and EEG fast-delta power in a narcolepsy mouse model. Piilgaard L; Rose L; Gylling Hviid C; Kohlmeier KA; Kornum BR Sleep; 2022 Jul; 45(7):. PubMed ID: 35266540 [TBL] [Abstract][Full Text] [Related]
15. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. Willie JT; Chemelli RM; Sinton CM; Tokita S; Williams SC; Kisanuki YY; Marcus JN; Lee C; Elmquist JK; Kohlmeier KA; Leonard CS; Richardson JA; Hammer RE; Yanagisawa M Neuron; 2003 Jun; 38(5):715-30. PubMed ID: 12797957 [TBL] [Abstract][Full Text] [Related]
17. Expression of a poly-glutamine-ataxin-3 transgene in orexin neurons induces narcolepsy-cataplexy in the rat. Beuckmann CT; Sinton CM; Williams SC; Richardson JA; Hammer RE; Sakurai T; Yanagisawa M J Neurosci; 2004 May; 24(18):4469-77. PubMed ID: 15128861 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of the efficacy of the hypocretin/orexin receptor agonists TAK-925 and ARN-776 in narcoleptic orexin/tTA; TetO-DTA mice. Sun Y; Ranjan A; Tisdale R; Ma SC; Park S; Haire M; Heu J; Morairty SR; Wang X; Rosenbaum DM; Williams NS; De Brabander JK; Kilduff TS J Sleep Res; 2023 Aug; 32(4):e13839. PubMed ID: 36808670 [TBL] [Abstract][Full Text] [Related]
19. Induction of narcolepsy-like symptoms by orexin receptor antagonists in mice. Kaushik MK; Aritake K; Cherasse Y; Imanishi A; Kanbayashi T; Urade Y; Yanagisawa M Sleep; 2021 Aug; 44(8):. PubMed ID: 33609365 [TBL] [Abstract][Full Text] [Related]
20. Design and Synthesis of Non-Peptide, Selective Orexin Receptor 2 Agonists. Nagahara T; Saitoh T; Kutsumura N; Irukayama-Tomobe Y; Ogawa Y; Kuroda D; Gouda H; Kumagai H; Fujii H; Yanagisawa M; Nagase H J Med Chem; 2015 Oct; 58(20):7931-7. PubMed ID: 26267383 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]